Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX001 open-label phase 2 study in adult non-neutropenic patients with candidemia
2017-003571-56Phase 2Completed
- Sponsor
- Amplyx Pharmaceuticals
- Start
- May 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fosmanogepix in candidemia and invasive candidiasis, sponsored by Amplyx Pharmaceuticals. Primary endpoint: Treatment success at EOST. Started May 2018; status: completed.
02
Drugs
fosmanogepix
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on 2017-003571-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003571-56.